Treatment Information

Back

Melanoma treatment details. Chemotherapy.

University of Tubingen, Tubingen, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:4City/State/Province:Tubingen
Treatments:ChemotherapyHospital:University of Tubingen
Drugs:Journal:Link
Date:Oct 2005

Description:

Patients: This Phase III study involved a total of 271 patients with metastatic melanoma who were divided into two groups: Group A of 137 patients and Group B of 134 patients. For Group B the median age was 58.

Treatment: The treatment for Group A consisted of one chemotherapy agent (Temozolomide).

Toxicity: Grade 4 toxicities for this group included: hematologic, and nausea.

Results: The median overall survival was 9.7 months.

Support: One author had acted as a consultnat for Schering Plough. This company markets interferon-alpha-2b.

Correspondence: Konstanze Spieth, MD




Back